Table II. Comparison of neutralization of SF162 and Tier 2 viruses by macaque polyclonal IgG and plasma from human subjects, VC10014 and VC20013.
| Viruses |
SF162 |
JRFL |
QH0692 |
YU2 |
|
|---|---|---|---|---|---|
| Tier 1 |
Tier 2 |
||||
| Plasma Time Points | Human Plasma ID50 | ||||
| VC10014 (1.19 EYa) | >2560 | 165 | 350 | 430 | |
| VC20013 (1.80 EYa) | >2560 | 940 | 935 | 620 | |
| Macaque ID | IC50 | Percent (%) Neutralizationa | |||
| VC10014 | 25740 | 8.5 | (−) | 40 | 16 |
| 26379 | ND | ND | ND | 20 | |
| 26429 | 3.0 | (−) | 49 | 16 | |
| 26433 | 5.3 | (−) | 40 | 17 | |
| 23640 | 2.7 | (−) | 39 | 10 | |
| 25257 | 2.6 | (−) | 43 | ND | |
| VC20013 | 23262 | 2.6 | 32 | 63 | ND |
| 24894 | 2.1 | 38 | 64 | ND | |
| 25900 | 1.6 | 34 | 58 | ND | |
| 27090 | 2.1 | 32 | 61 | ND | |
| 27242 | 6.5 | 17 | 46 | ND | |
| 26465 | 3.0 | 28 | 63 | ND | |
a
Percent neutralization by macaque IgG at 1 mg/ml.
EY, time (y) since infection that the plasma sample was obtained and tested (53); IC50, concentration (mg/ml) that leads to 50% neutralization; ID50, plasma dilution that leads to 50% neutralization; ND, no data.